Bionomics Limited - American Depository Sh… stock is up 14.43% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 March’s closed higher than February.
Bionomics Limited discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trials for social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the. treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed. phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!